162 (1.119.206) 0.50 0.71 1.0 1.41 2.0 Age Gender Grade Stage T M N riskScore pvalue 0.212 0.489 0.141 0.928 0.229 0.102 0.765 0.001 CYP3 drug Hazard ratio 1.010 (0.995.025) 0.871 (0.589.288) 1.231 (0.9341.623) 0.960 (0.393.345) 1.689 (0.719.968) 1.245 (0.958.620) 1.042 (0.797.361) 1.154 (1.106.203) 0.50 1.0 2.0 four.Hazard ratioHazard ratio(a)30 20 10 0 =65 Age Age =65 65 Gender MALE FEMALE 65 0.041 30 20 ten 0 MALE FEMALE Gender 0.(b)30 six.5e-riskScoreriskScoreriskScore0 G1-2 Grade Grade G1-2 G3-4 G3-(c)30 20 10 0 Stage I-II Stage III-IV Stage Stage Stage I-II Stage III-IV 3.8e(d)30 0.(e)riskScoreriskScore0 T1-2 T T T1-2 T3-4 T3-(f )(g)Figure 3: Continued.Patients with MALE Survival probability Survival probability 1.00 0.75 0.50 0.25 0.00 0 riskScore high low 1 2 three 4 5 6 4 7 two eight 1 1 eight 9 10 riskScore 1 1 1 0 higher low Time (years) 103 54 25 18 10 six 130 108 55 39 32 20 13 2 0 1 two 3 4 5 6 7 p 0.001 1.00 0.75 0.50 0.25 0.00 0 1 2 three four five eight six 6 7 3 8 two two eight 9 10 1 1 1 0 riskScore high low Time (years) 87 42 27 14 11 126 one hundred 54 40 30 20 13 three 0 1 two three 4 5 six 7 p 0.001 Individuals with G1 Survival probability 1.00 0.75 0.50 0.25 0.00 0 1 two three 4 p = 0.001 Individuals with G3Journal of Oncology56 4 37 2 18 1 19 10 1 1 1Time (years) 84 59 25 16 9 45 40 20 14 11 six 0 1 2 3 4999Time (years) riskScore high low Individuals with M0 Survival probability Survival probability 1.00 0.75 0.50 0.25 0.00 0 riskScore higher low 1 2 three 4 5 six 7 eight 3 three eight 9 10 riskScore two two 1 0 higher low Time (years) 136 80 43 27 18 12 ten 5 125 107 57 41 35 22 13 4 0 1 two 3 4 five 6 7 p 0.001 1.00 0.75 0.50 0.25 0.00 0 1 two 3 p 0.001 riskScore high low Sufferers with NTime (years) riskScore higher lowTime (years)Individuals with Stage I I Survival probability 1.00 0.75 0.50 0.25 0.00 0 riskScore high low 1 two three 4 five 6 7 4 8 2 2 eight 9 10 1 2 0 0 Time (years) 5 3 3 eight 2 two 1 0 112 74 38 24 15 ten 8 140 115 62 45 34 21 13 3 0 1 2 three four five six 7 p 0.9Time (years) 131 76 41 25 17 11 9 120 105 56 43 35 22 13 four 0 1 two 3 four 5 6999Time (years) riskScore high low Individuals with Stage III-IV Survival probability Survival probability 1.00 0.75 0.50 0.25 0.00 0 riskScore higher low 1 two three four 5 6 7 4 8 two two 8 9 ten riskScore 1 two 0 0 high low Time (years) 112 74 38 24 15 20 8 59 27 14 six 31 25 12 9 0 1 two three 140 115 62 45 34 21 13 3 0 1 two 3 4 five six 7 p = 0.001 1.00 0.75 0.50 0.25 0.00 0 1 two three p 0.001 riskScore higher lowTime (years) riskScore high lowTime (years)Individuals with T1 Survival probability 1.00 0.75 0.50 0.25 0.Sufferers with T3p 0.001 0 1 two 3 4 5 six 7 4 8 2 2 eight 9 ten 1 2 04 5 75 2 56 two 37 1 18 1 19 ten riskScore 1 0 1 0 high lowTime (years)Time (years) 115 76 40 24 15 10 eight 141 115 62 45 34 21 13 3 0 1 2 three 4 five 6999Time (years) riskScore high low riskScore high lowTime (years) riskScore high lowTime (years)(h)Figure 3: Connection involving threat score and clinicopathological characteristics. Univariate Cox hazard evaluation (a) and multivariate Cox hazard evaluation (b) of patient’s features. e distribution of risk score in various ages (c), genders (d), grades (e), stages (f ), and T (g) has a considerable GLUT4 Biological Activity distinction. (h) e danger score can predict the survival of individuals in different age, gender, histological grade, M0, N0, stage, and T patients.Journal of OncologyEnrichment plot: KEGG_DRUG_ METABOLISM_CYTOCHROME_P450 0.0 .1 .2 .three .4 .5 .6 .7 0.0 .1 .two .3 .four .five .6 .7 Enrichment score (ES) Enrichment score (ES) Enrichment plot: KEGG_COMPLEMENT_ AND_COAGULATION_CASCADES 0.0 .1 .2 .three .4 .five .6 .7 Enrichment score (ES) Enrichment plot: KEGG_RETINOL_METABOLISMRanked list
